Conference Proceedings
Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.
Paul M Barr, Talha Munir, Jennifer R Brown, Susan Mary O'Brien, Jacqueline Claudia Barrientos, Nishitha M Reddy, Steven Coutre, Constantine Si Lun Tam, Stephen P Mulligan, Ulrich Jager, Thomas J Kipps, Carol Moreno, Marco Montillo, Jan Andreas Burger, John C Byrd, Peter Hillmen, Sandra Dai, Anita Szoke, James P Dean, Jennifer Ann Woyach
JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2019
Abstract
7510 Background: Ibrutinib (ibr), a first-in-class, once-daily Bruton’s tyrosine kinase inhibitor, has redefined treatment paradigms for CLL/SLL. We report final analysis with up to 6 years of follow-up on ibr from the phase 3 RESONATE study of single-agent ibr vs ofatumumab (ofa) in pts with relapsed/refractory (R/R) CLL/SLL. Methods: Pts were randomized to receive oral ibr 420 mg daily until PD or intravenous ofa for up to 24 weeks. Long-term efficacy endpoints were investigator-assessed. Results: Among 391 pts randomized to receive ibr (n=195) or ofa (n=196), 86% and 79%, respectively, were in the genomic high-risk population (del(17p), del(11q), TP53 mutation, and/or unmutated IGHV). At..
View full abstract